SRC inhibitors(Tyrosine-protein kinase SRC inhibitors), p38α inhibitors(P38 α mitogen-activated protein kinase inhibitors), p38γ inhibitors(P38 γ mitogen-activated protein kinase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [1]

Active Indication-

Inactive Indication

Pulmonary Disease, Chronic ObstructiveRespiratory Syncytial Virus InfectionsRhinitis, Allergic, Seasonal+ [1]

Originator Organization

RespiVert Ltd.

Active Organization-

Inactive Organization

Janssen Research & Development LLC

RespiVert Ltd.

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Structure

Molecular FormulaC34H36N6O4

InChIKeyRTDCVLCTBQDLBW-UHFFFAOYSA-N

CAS Registry1220626-82-3

Clinical Trials associated with RV-568

NCT01867762 / CompletedPhase 2

A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Inhaled JNJ 49095397 (RV568) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

The purpose of this study is to assess the effectiveness and safety of JNJ 49095397 in participants with symptomatic moderate to severe chronic obstructive pulmonary disease (COPD).

Start Date09 Sep 2013

Sponsor / Collaborator

Janssen Research & Development LLC

NCT01661244 / CompletedPhase 1

A Randomised, Double-blind, Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV568 in Healthy Volunteers

RV568 is being developed as a possible treatment of smoking related lung disease (also known as Chronic Obstructive Pulmonary Disease - COPD).
The main purpose of this study is to examine the safety and tolerability of a new inhaled formulation of RV568 in healthy volunteers. The study will be run in two parts; Part A and Part B. Part A (Cohorts 1, 2 & 3) will investigate 6 different dose levels of RV568 given as a single dose and Part B (Cohorts 4 & 5) will investigate 2 different dose levels of RV568 given once a day for 14 days.

Start Date01 Sep 2012

Sponsor / Collaborator

RespiVert Ltd.

NCT01475292 / CompletedPhase 2

A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Treatment With Repeat Doses of Inhaled RV568 in Patients With COPD

RV568 is being developed as a possible treatment of diseases such as smoking related lung disease (also known as Chronic Obstructive Pulmonary Disease - COPD) and asthma.
The main purpose of this study is to examine the safety of RV568 in COPD patients. Two dose strengths of RV568 and a placebo will be tested in this study, which will be given by inhaling a liquid suspension from a nebuliser once a day for 2 weeks.

Start Date01 Nov 2011

Sponsor / Collaborator

RespiVert Ltd.

100 Clinical Results associated with RV-568

100 Translational Medicine associated with RV-568

100 Patents (Medical) associated with RV-568

Literatures (Medical) associated with RV-568

04 Mar 2015·Expert opinion on investigational drugsQ2 · MEDICINE

Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease

Q2 · MEDICINE

Review

Author: Norman, Peter

INTRODUCTION:

The p38 protein kinases, in particular p38α and p38β, regulate the production of multiple inflammatory mediators. Consequentially, considerable effort has been focused on trying to develop p38 inhibitors for the treatment of inflammatory diseases. Some 20 p38 inhibitors have progressed to clinical development, mostly for the treatment of rheumatoid arthritis, but with little success. Increasingly, interest has turned to their use in other indications and notably chronic obstructive pulmonary disease (COPD).

AREAS COVERED:

In this review, the author discusses the eight p38 inhibitors that have been clinically evaluated. Acumapimod is the only one of four orally delivered inhibitors that remains in active development while Phase II results of PH-797804 and losmapimod are compared. The activity of two inhibitors designed for inhaled delivery, RV-568 and PF-03715455, is compared but little is known about AZD-7624 or the discontinued GSK-610677.

EXPERT OPINION:

Results from animal models provide a clear rationale for developing p38 inhibitors for COPD, and appear to be (partially) validated by the efficacy seen with PH-797804 and losmapimod. Inhaled delivery provides the opportunity to enhance p38 inhibition in the lung while reducing unwanted systemic effects of p38 inhibition. Validation of this hypothesis should come from the results of the recently completed Phase II study with RV-568.

01 Dec 2014·Expert opinion on therapeutic patentsQ2 · MEDICINE

Respivert’s multikinase inhibitors, an evaluation of WO2014033446 to WO2014033449

Q2 · MEDICINE

Article

Author: Norman, Peter

These four patent applications all claim that N-aryl-N'-pyrazol-5-yl urea derivatives , related to RV-568, which are inhibitors of p38, Syk and Src kinases. All four applications claim their use in the treatment of inflammatory diseases, notably asthma and chronic obstructive pulmonary disease. The four applications are primarily differentiated by the claimed substitution of the pyrazole ring. This is accompanied by differential kinase specificity profiles. Many of the exemplified compounds show reduced potency as p38 inhibitors but high potency as inhibitors of Syk and/or Src kinases.

100 Deals associated with RV-568

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 2	GB	RespiVert Ltd.	01 Nov 2011
Rhinitis, Allergic, Seasonal	Phase 2	AT	RespiVert Ltd.	01 Oct 2010
Seasonal rhinitis	Phase 2	AT	RespiVert Ltd.	01 Oct 2010
Respiratory Syncytial Virus Infections	Phase 1	GB	RespiVert Ltd.	01 Oct 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


RV568 (ERS2013)	Not Applicable	IL8 \| IL6 \| viral load ... View more	42	RV568 400µg	xatnbcyhxc(nhlgpvqltf) = vumhoxlguv ixregfzbjq (gyugobyjrm )	Positive	01 Sep 2013
				Placebo	xatnbcyhxc(nhlgpvqltf) = ggbwzfejyg ixregfzbjq (gyugobyjrm )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

RV-568

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation